Literature DB >> 20450124

First report of screening an asymptomatic population for cancer: the yield of an integrated cancer prevention center.

Ben Boursi1, Hanan Guzner-Gur, Yaquv Mashich, Udi Miler, Eyal Gur, Roy Inbar, Arye Blachar, Fanny Sperber, Shlomi Kleiman, Ariel Yafo, Hanoch Elran, Tal Sella, Inna Naumov, Diana Kazanov, Sarah Kraus, Lior Galazan, Netta Reshef, Tali Sion-Tadmor, Miri Rozen, Eliezer Liberman, Menachem Moshkowitz, Nadir Arber.   

Abstract

BACKGROUND: Cancer is a leading cause of mortality worldwide. The most effective way to combat cancer is by prevention and early detection.
OBJECTIVES: To evaluate the outcome of screening an asymptomatic population for the presence of benign and neoplastic lesions.
METHODS: Routine screening tests for prevention and/or early detection of 11 common cancers were conducted in 300 consecutive asymptomatic apparently healthy adults aged 25-77 years. Other tests were performed as indicated.
RESULTS: Malignant and benign lesions were found in 3.3% and 5% of the screenees, respectively, compared to 1.7% in the general population. The most common lesions were in the gastrointestinal tract followed by skin, urogenital tract and breast. Advanced age and a family history of a malignancy were associated with increased risk for cancer with an odds ratio of 9 and 3.5, respectively (95% confidence interval 1.1-71 and 0.9-13, respectively). Moreover, high serum C-reactive protein levels and polymorphisms in the APC and CD24 genes indicated high cancer risk. When two of the polymorphisms existed in an individual, the risk for a malignant lesion was extremely high (23.1%; OR 14, 95% CI 2.5-78).
CONCLUSIONS: Screening asymptomatic subjects identifies a significant number of neoplastic lesions at an early stage. Incorporating data on genetic polymorphisms in the APC and CD24 genes can further identify individuals who are at increased risk for cancer. Cancer can be prevented and/or diagnosed at an early stage using the screening facilities of a multidisciplinary outpatient clinic.

Entities:  

Mesh:

Year:  2010        PMID: 20450124

Source DB:  PubMed          Journal:  Isr Med Assoc J            Impact factor:   0.892


  4 in total

1.  Promoting early detection of melanoma during the mammography experience.

Authors:  A K Rzepecki; N Jain; Y Ali; L Chavez; J Choi; B Schlosser; E Liko-Hazizi; S M Friedewald; J K Robinson
Journal:  Int J Womens Dermatol       Date:  2017-07-05

2.  Chemiluminescence enzyme immunoassay based on magnetic nanoparticles for detection of hepatocellular carcinoma marker glypican-3.

Authors:  Qian-Yun Zhang; Hui Chen; Zhen Lin; Jin-Ming Lin
Journal:  J Pharm Anal       Date:  2011-07-22

3.  Effectiveness of One-Stop Screening for Colorectal, Breast, and Prostate Cancers: A Population-Based Feasibility Study.

Authors:  Joseph J Y Sung; Arthur K C Luk; Simon S M Ng; Anthony C F Ng; Peter K F Chiu; Emily Y Y Chan; Polly S Y Cheung; Winnie C W Chu; Sunny H Wong; Thomas Y T Lam; Samuel Y S Wong
Journal:  Front Oncol       Date:  2021-02-25       Impact factor: 6.244

4.  Variants in the Signaling Protein TSAd are Associated with Susceptibility to Ovarian Cancer in BRCA1/2 Negative High Risk Families.

Authors:  Ludmila Kaplun; Aviva Levine Fridman; Wei Chen; Nancy K Levin; Sidra Ahsan; Nancie Petrucelli; Jennifer L Barrick; Robin Gold; Susan Land; Michael S Simon; Robert T Morris; Adnan R Munkarah; Michael A Tainsky
Journal:  Biomark Insights       Date:  2012-12-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.